Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers

International Journal of Antimicrobial Agents

Volumn 40, Issue 1, 2012, Pages 51-54

  Sahre, Martina ^a   Sabarinath, Sreedharan ^a   Grant, Maria ^b   Seubert, Christoph ^b   DeAnda, Carisa ^c   Prokocimer, Philippe ^c   Derendorf, Hartmut ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c Trius Therapeutics Inc   (United States)

Author keywords

Microdialysis; Pharmacokinetics; Tedizolid; Tissue distribution

Indexed keywords

TEDIZOLID;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIALYSATE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; INTERSTITIAL FLUID; MALE; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SINGLE DRUG DOSE; SKIN EXAMINATION; SOFT TISSUE; SUBCUTANEOUS FAT; TIME TO MAXIMUM PLASMA CONCENTRATION; VASTUS MEDIALIS MUSCLE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; EXTRACELLULAR FLUID; FEMALE; HUMAN EXPERIMENTATION; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; OXAZOLIDINONES; SUBCUTANEOUS FAT; TETRAZOLES; TIME FACTORS; YOUNG ADULT;

EID: 84861889145     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2012.03.006     Document Type: Article

References (27)

1. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-85.
2. Kallen AJ, Mu Y, Bulens S, Reingold A, Petit S, Gershman K, et al. Health care-associated invasive MRSA Infections, 2005-2008. JAMA 2010;304:641-7.
3. Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996;40:839-45. (Pubitemid 26117523)
4. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003;51(Suppl. 2):ii17-25. (Pubitemid 36622108)
5. Dehghanyar P, Burger C, Zeitlinger M, Islinger F, Kovar F, Muller M, et al. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob Agents Chemother 2005;49:2367-71. (Pubitemid 40734468)
6. Pfizer. Zyvox® prescribing information. New York, NY: Pfizer; 2010. http://www.pfizerpro.com/hcp/zyvox [accessed 03.04.12].
7. Yum JH, Choi SH, Yong D, Chong Y, Im WB, Rhee DK, et al. Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea. Antimicrob Agents Chemother 2010;54:5381-6.
8. Merrikin DJ, Briant J, Rolinson GN. Effect of protein binding on antibiotic activity in vivo. J Antimicrob Chemother 1983;11:233-8. (Pubitemid 13161697)
9. Chisholm GD, Waterworth PM, Calnan JS, Garrod LP. Concentration of antibacterial agents in interstitial tissue fluid. Br Med J 1973;1:569-73.
10. Ryan DM. Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. J Antimicrob Chemother 1993;31(Suppl. D):1-16. (Pubitemid 23193749)
11. Chaurasia CS, Muller M, Bashaw ED, Benfeldt E, Bolinder J, Bullock R, et al. AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res 2007;24:1014-25. (Pubitemid 46675390)
12. Barbour A, Schmidt S, Sabarinath SN, Grant M, Seubert C, Skee D, et al. Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis. Antimicrob Agents Chemother 2009;53:2773-6.
13. Eisenberg EJ, Conzentino P, Eickhoff WM, Cundy KC. Pharmacokinetic measurement of drugs in lung epithelial lining fluid by microdialysis: aminoglycoside antibiotics in rat bronchi. J Pharmacol Toxicol Methods 1993;29:93-8. (Pubitemid 23161862)
14. Stolle LB, Plock N, Joukhadar C, Arpi M, Emmertsen KJ, Buerger C, et al. Pharmacokinetics of linezolid in bone tissue investigated by in vivo microdialysis. Scand J Infect Dis 2008;40:24-9.
15. Tegeder I, Schmidtko A, Brautigam L, Kirschbaum A, Geisslinger G, Lotsch J. Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther 2002;71:325-33. (Pubitemid 34518143)
16. Thallinger C, Buerger C, Plock N, Kljucar S, Wuenscher S, Sauermann R, et al. Effect of severity of sepsis on tissue concentrations of linezolid. J Antimicrob Chemother 2008;61:173-6.
17. US Food and Drug Administration. Challenge and opportunity on the critical path to new medical products. Silver Spring, MD: FDA; 2004.
18. European Medicines Agency. Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products. London, UK: Committee for Proprietary Medicinal Products (CPMP); 2000.
19. Prokocimer P, Bien P, Surber J, Mehra P, DeAnda C, Bulitta JB, et al. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2011;55:583-92.
20. Ståhle L, Arner P, Ungerstedt U. Drug distribution studies with microdialysis III: extracellular concentration of caffeine in adipose tissue in man. Life Sci 1991;49:1853-8.
21. Bien P, Munoz KA, Bohn J, Wright R, Bethune C, Prokocimer P. Human pharmacokinetics of TR-700 after ascending single oral doses of the prodrug TR-701, a novel oxazolidinone antibiotic. In: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC: ASM Press; 2008.
22. Bien P, Prokocimer P, Munoz KA, Bethune C. Absolute bioavailability of TR-701 FA and pharmacokinetics after single and multiple dose intravenous administration in healthy adult subjects. In: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC: ASM Press; 2010.
23. Stalker DJ, Jungbluth GL, Hopkins NK, Batts DH. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 2003;51:1239-46. (Pubitemid 36622080)
24. Gresham HD, Lowrance JH, Caver TE, Wilson BS, Cheung AL, Lindberg FP. Survival of Staphylococcus aureus inside neutrophils contributes to infection. J Immunol 2000;164:3713-22. (Pubitemid 30169827)
25. Lemaire S, Van Bambeke F, Appelbaum PC, Tulkens PM. Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. J Antimicrob Chemother 2009;64:1035-43.
26. Bien P, DeAnda C, Prokocimer P. Microbiological efficacy of torezolid in patients with complicated skin and skin structure infections. In: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases; 2010 [Abstract P1592].
27. Nicasio AM, Bulitta JB, Lodise TP, D'Hondt RE, Kulawy R, Louie A, et al. Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model. Antimicrob Agents Chemother 2012;56:682-6.